The DOI matches its Crossref record.
Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
Open accessAbstract
BACKGROUND: The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptoms. METHODS: A total of 201 patients with Crohn's Disease Activity Index (CDAI) scores between 250 and 450 were randomized to receive an initial intravenous dose of 1.0 or 4.0 mg/kg fontolizumab or placebo, followed by up to 3 subcutaneous doses of 0.1 or 1.0 mg/kg fontolizumab or placebo every 4 weeks. Clinical response at day 29, the primary efficacy endpoint, was defined as a decrease in the CDAI of at least 100 points from baseline levels. RESULTS: Of 201 patients, 135 (67%) completed the study. Day 29 response rates were similar in all treatment groups (31%-38%). At subsequent timepoints a significantly greater proportion of patients in the 1.0 mg/kg intravenous / 1.0 mg/kg subcutaneous fontolizumab group had clinical response and significantly greater improvement in the CDAI score compared with patients who received placebo. All fontolizumab groups had significant improvement in C-reactive protein levels. The overall frequency of adverse events was similar in all groups (58%-75%); most events were related to exacerbation of CD. There was a low frequency (5.2%) of neutralizing antibodies to fontolizumab. CONCLUSIONS: Although a strong clinical response to fontolizumab was not observed, significant decreases in C-reactive protein levels suggest a biological effect. Fontolizumab was well tolerated, and further studies to assess its efficacy are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases
Strober, W., & Fuss, I. J. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.016 · Cited by 1,102
Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Friedrich, M., Pohin, M., & Powrie, F. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.017 · Cited by 750
Luissint, A.-C., Parkos, C. A., & Nusrat, A. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.07.008 · Cited by 555
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
Moschen, A. R., Tilg, H., & Raine, T. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0084-8 · Cited by 473
Metadata
- Authors
- Reinisch, W., de Villiers, W., Bene, L., Simon, L., Rácz, I., Katz, S., Altorjay, I., Feagan, B., Riff, D., Bernstein, C. N., Hommes, D., Rutgeerts, P., Cortot, A., Gaspari, M., Cheng, M., Pearce, T., & Sands, B. E.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-02
- Volume
- 16
- Issue
- 2
- Pages
- 233-242
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2117966967
- Cited by
- 220
- References
- 0
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. https://app.cochat.ai/papers/10.1002/ibd.21038
- The paper
- Reinisch, W., de Villiers, W., Bene, L., Simon, L., Rácz, I., Katz, S., Altorjay, I., Feagan, B., Riff, D., Bernstein, C. N., Hommes, D., Rutgeerts, P., Cortot, A., Gaspari, M., Cheng, M., Pearce, T., & Sands, B. E. (2010). Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflammatory Bowel Diseases. https://doi.org/10.1002/ibd.21038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.